Anzeige
Mehr »
Login
Freitag, 03.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Schnelle Produktionsaufnahme: Multi-Tenbagger-Potenzial direkt in Spanien?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
19 Leser
Artikel bewerten:
(0)

Global Med Technologies(R), Inc. Files Post Effective Amendment Related to Previously Registered Shares


DENVER, June 1 /PRNewswire-FirstCall/ -- Global Med Technologies(R), Inc. ("Global Med" or the "Company") (BULLETIN BOARD: GLOB) , today announced that it has filed a post effective amendment related to previously registered shares. This registration statement does not provide for the issuance of any additional common shares but seeks to maintain registration on the common shares underlying the Series A Convertible Preferred Stock ("Series A") and the warrants issued as part of the financing agreement that took place in December of 2005. This financing eliminated $814,000 in annual dividend and interest payments and approximately 4.86 million shares of the Company's common stock.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO )

The Company's Chairman and CEO, Michael I. Ruxin, M.D., commented, "This post effective registration statement seeks to maintain registration on warrants and the Series A issued as part of the December 2005 financing and provides for no further dilution."

About Global Med Technologies, Inc.

Global Med Technologies, Inc. is an international e-Health medical information technology company providing information management software products and services to the healthcare industry. Its Wyndgate Technologies division is a leading supplier of information management systems to U.S. and International blood centers and hospital transfusion centers. Each year, Wyndgate's products and services manage more than eight million blood components, representing over 27% of the U.S. blood supply. Wyndgate's products are being used in Canada and sub-Saharan Africa, and are being implemented in the Caribbean. Together, the SafeTrace Tx*(R) advanced transfusion management system and the SafeTrace(R) donor management system provide Vein-to-Vein(R) tracking from donor collection to patient transfusion.

For more information about Global Med's products and services, please call 800-WYNDGATE or visit http://www.globalmedtech.com/, http://www.peoplemed.com/ and http://www.wyndgate.com/.

This news release may include statements that constitute forward-looking statements, usually containing the words "believe," "estimate," "project," "expects" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this news release.

*Patent Pending Company Contact: Investor Contact: Global Med Technologies, Inc. Paul Holm Michael I. Ruxin, M.D. H.L. Lanzet (303) 238-2000 (212) 888-4570paulmholm@gmail.com
Photo: http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, photodesk@prnewswire.com

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2007 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.